KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $151.4 million.

  • Supernus Pharmaceuticals' Cash & Equivalents rose 37791.81% to $151.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.4 million, marking a year-over-year increase of 37791.81%. This contributed to the annual value of $69.3 million for FY2024, which is 762.52% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Cash & Equivalents stood at $151.4 million, which was up 37791.81% from $144.7 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash & Equivalents peaked at $255.6 million during Q1 2021, and registered a low of $24.7 million during Q2 2023.
  • For the 5-year period, Supernus Pharmaceuticals' Cash & Equivalents averaged around $119.7 million, with its median value being $111.5 million (2022).
  • Per our database at Business Quant, Supernus Pharmaceuticals' Cash & Equivalents plummeted by 8575.43% in 2023 and then skyrocketed by 37791.81% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Cash & Equivalents (Quarter) stood at $203.4 million in 2021, then tumbled by 54.23% to $93.1 million in 2022, then decreased by 19.4% to $75.1 million in 2023, then decreased by 7.63% to $69.3 million in 2024, then soared by 118.33% to $151.4 million in 2025.
  • Its Cash & Equivalents was $151.4 million in Q3 2025, compared to $144.7 million in Q2 2025 and $115.8 million in Q1 2025.